Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q3 2019 Earnings Presentation
12 slides from Marinomed Biotech's earnings presentation, Nov 29, 2019
Slide 1: Results for the first three quarters 2019
Creating innovative therapies for allergy, respiratory and eye diseases Results for the first three quarters 2019 Investor Presentation Vienna, 29 November 2019
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Highlights Q1-3 2019
Highlights Q1-3 2019 Important milestones provide basis for accelerated development going forward €37.4m Phase III >40 Data published at Financing through countries launched ACAAI, Houston IPO and EIB €3.3m New Property revenue Q3 €1.7m found vs. H1 €1.7m in Korneuburg, relocation in 2020 On track 1
Slide 4: Data published at ACAAI in Houston
Data published at ACAAI in Houston Non-inferiority and early onset of Budesolv compared to originator and placebo Figure A: TNSS1 Budesolv with 85% less active ingredient and same effect Lower symptom score is better On day 8, Budesolv shows the same *** *** significant improvement of symptoms a
Slide 5: Budesolv addressing an underserved market
Budesolv addressing an underserved market With Budesolv's fast onset of action, steroid acceptance of patients could rise significantly Actual Target With the availability of Budesolv, a nasal steroid Guidelines, health care professionals and with fast onset of action can be used according to ph
Slide 6: Carragelose products continue expansion
Carragelose® products continue expansion Multiple additional launches and line extensions planned in the coming years Currently marketed in over 40 countries Initiatives Advanced discussions with additional partners in multiple regions Studies for nasal sprays and lozenges to allow regional part
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) €m 9M 2019 9M 2018 1 Revenue €m 9M 2019 9M 2018 Revenues 1 3.3 3.2 Sale of goods 3.0 3.1 Other income 0.5 0.6 License revenues 0.1 0.1 Other net gains/losses 0.0 0.0 Other revenues 0.2 0.1 Materials and services expenses 2 (4.4) (3.3) Total revenue 3.3 3.2 Personne
Slide 8: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q3 2019 YE 2018 1 Acquisition of property in Korneuburg Assets 2 Therein Austrian Research Promotion in the amount Intangible assets 1.4 1.3 of €0.8m (YE 2018: €0.5m) Property, plant and equipment 1 1.6 0.2 3 Not yet taking into account any disburseme
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q3 2019 YE 2018 1 Therein IPO related paid-in capital of €20.3m (net of transaction costs) and conversion of the Equity and liabilities convertible bond in the amount of €13.1m Share capital 1.5 1.0 Capital reserves 40.7 7.0 2 Primaril
Slide 10: Statement of cash flows (IFRS)
Statement of cash flows (IFRS) Net Cash at Net change in Net D&A Cash at beginning Loss for financial working interest and Investing Financing end of of period the period result capital paid other cash flow cash flow period 10
Slide 11: Outlook
Outlook Investments in Marinosolv® and commercialisation of Carragelose® We are investing in R&D R&D investments were ramped up by more than €1mio from 2018 to 2019 in the Q1-Q3 period and we expect a further increase Tacrosolv shall start clinical development in H1 2020 We are building our ne
Slide 12: www.marinomed.com
: Orrarino www.marinomed.com